Workflow
Arcadis shareholders appoint Simon Crowe as new CFO and member of the Executive Board
Globenewswire· 2025-09-30 10:46
核心人事任命 - Arcadis股东任命Simon Crowe为首席财务官及执行董事会成员 [1] - Simon Crowe的执行董事会任期为四年 并立即生效 [2] - 该提名最初于2025年8月5日公布 [2] 公司基本情况 - Arcadis是全球领先的提供数据驱动的可持续设计、工程和咨询解决方案的公司 [3] - 公司拥有超过35,000名员工 涵盖建筑师、数据分析师、设计师、工程师等多个专业领域 [3] - 公司2024年总营业收入为50亿欧元 [3] 业务运营与战略重点 - 公司业务重点包括环境、能源与水、建筑、交通和基础设施领域 [3] - 公司致力于通过结合数字与人力创新 加速实现地球积极未来 [3] - 公司在超过30个国家开展业务 [3] 投资者关系与财务日历 - 公司将于2025年10月30日发布2025年第三季度交易更新 [6] - 公司将于2026年2月19日公布2025年第四季度及全年业绩 [6] - 公司将于2026年4月30日发布2026年第一季度交易更新 [6]
Filing of the Groupama 2025 Half Year Financial Report
Globenewswire· 2025-09-30 10:44
Groupama announces its Half Year Financial Report for 2025 is now available on its website and has been filed with the French stock exchange regulatory authority, l’Autorité des Marchés Financiers. This document includes the half year 2025 combined financial statements, the half year activity report, the declaration by the person responsible for the Half Year Financial Report as well as the statutory auditors’ review on the half year financial information. The Half Year Financial Report can be viewed in Fre ...
INNEOVA Holdings Delivers Robust 10.3% Revenue Growth in First Half of Fiscal Year 2025
Globenewswire· 2025-09-30 10:30
SINGAPORE, Sept. 30, 2025 (GLOBE NEWSWIRE) -- INNEOVA Holdings Limited (“INNEOVA Holdings” or the “Company”) (Nasdaq: INEO), a Singapore-based solutions provider focused on maximising uptime, optimising total cost of ownership, and extending asset longevity through sustainable engineering, today announced its unaudited financial results for the six months ended June 30, 2025. Key Financial Highlights for the First Half of 2025 Revenue: $30.8 million, a 10.3% increase from $27.9 million in the prior year per ...
Abaxx Announces $30.7 Million Strategic Financing
Globenewswire· 2025-09-30 10:30
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Abaxx Technologies Inc. (CBOE:ABXX) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, is pleased to announce today it has entere ...
3D at Depth is now Kraken Robotics
Globenewswire· 2025-09-30 10:30
ST. JOHN’S, Newfoundland and Labrador, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Kraken Robotics Inc. (“Kraken” or the “Company”) (TSX-V: PNG, OTCQB: KRKNF) announces that, following its acquisition of 3D at Depth on April 1, 2025, the 3D at Depth brand and company name have changed to Kraken Robotics. Clients can now access Kraken’s full suite of marine technology products and services—from synthetic aperture sonar and subsea batteries to LiDAR solutions and sub-bottom imaging. There are no changes to LiDAR solut ...
BranchOut Launches New Crunchy Fruit Multipack for Warehouse Club Expansion
Globenewswire· 2025-09-30 10:30
New multipack, aimed at expansion into front-of-store, doubles BranchOut’s reach in warehouse clubsBEND, Ore., Sept. 30, 2025 (GLOBE NEWSWIRE) -- BranchOut Food Inc. (NASDAQ: BOF), a leading food technology company specializing in its patented GentleDry™ dehydrated snacks and ingredients, is excited to announce the launch of its new Crunchy Fruit Multipack, featuring 18 convenient snack-sized bags of BranchOut’s best-selling fruit crisps: Crunchy Pineapple, Crunchy Strawberry, and Crunchy Banana. This new i ...
Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint
Globenewswire· 2025-09-30 10:21
SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026 Event to detail how robust SOL-R patient selection strategy, trial design, and potential SOL-1 success could drive confidence in SOL-R outcomes; topline data on track for 1H 2027 Will showcase planned HELIOS-2 and HELIOS-3 registrational trials to evaluate AXPAXLI in non-proliferative diabetic retinopathy (NPDR) us ...
HRC WORLD PLC: RESULTS OF ANNUAL GENERAL MEETING
Globenewswire· 2025-09-30 10:00
HRC WORLD PLC NASDAQ FIRST NORTH, COPENHAGEN TICKER: HRCISIN: GB00BZ3CDY20 30 September 2025 RESULTS OF ANNUAL GENERAL MEETING The Board of Directors of HRC World Plc (“HRC” or the “Company” or the “Group”), are pleased to announce that its Annual General Meeting ("AGM") was held in Kuala Lumpur earlier today, 30 September 2025. Details of the resolutions to be considered at the AGM were published in the Notice of AGM on 27 August 2025, which is available on the Company's website at http://www.hrcplc.co.uk. ...
Fortis Inc. to Hold Teleconference on November 4 to Discuss Third Quarter 2025 Results and New Five-Year Capital Outlook
Globenewswire· 2025-09-30 10:00
ST. JOHN'S, Newfoundland and Labrador, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Fortis Inc. ("Fortis" or the "Corporation") (TSX/NYSE: FTS) will release its third quarter 2025 financial results and new five-year capital outlook for the period 2026-2030 on Tuesday, November 4, 2025. A teleconference and webcast will be held the same day at 8:30 a.m. (Eastern). David Hutchens, President and Chief Executive Officer and Jocelyn Perry, Executive Vice President and Chief Financial Officer will discuss the Corporation's ...
Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal 
Globenewswire· 2025-09-30 10:00
ORION CORPORATION PRESS RELEASE 30 SEPTEMBER 2025 at 13.00 EEST Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal Orion to discontinue development of ODM-105 for insomnia.ODM-105 (tasipimidine) was well tolerated. Detailed results, including safety data, and their assessment are to be finalized. Orion Corporation today announced that its candidate ODM-105 (tasipimidine) did not meet the primary goal in the clinical Phase 2 UNITAS study for the treatment of patients with insomnia. Acco ...